Form D · Biotechnology
GenoSpace, LLC
Cambridge, MA · CIK 0001616540
Offering snapshot reported Aug 14, 2014 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 7, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 14, 2014 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-222918
Source: Form D, filed Aug 14, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mick Correll | Director, Executive |
| Daniel Meyer | Director, Executive |
| John Quackenbush | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
700 Massachusetts Avenue, Third Floor
Cambridge, MA, 02139
Cambridge, MA, 02139